Drugs / Alpha-1 MP
Alpha-1 MP
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02870309 | Jul 2016 → Mar 2017 | alpha 1-antitrypsin deficiency | Grifols Therapeutics LLC | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02796937 | Jul 2016 → Sep 2028 expected | pulmonary emphysema | Grifols Therapeutics LLC | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT01983241 | Nov 2013 → Aug 2026 overdue | pulmonary emphysema | Grifols Therapeutics LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00295061 | May 2006 → Feb 2007 | alpha 1-antitrypsin deficiency | Grifols Therapeutics LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha-1 MP | “Sequential, blinded treatment periods of Alpha-1 MP (experimental), then crossed-over to Prolastin (active comparator), followed by open-label Alpha-1 MP” NCT00295061 ↗ |
| Known as | Alpha1-proteinase Inhibitor (Human), Modified Process | “Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process)” NCT02870309 ↗ |
| Known as | Alpha1-Proteinase Inhibitor, Modified Process | “Alpha1-Proteinase Inhibitor, Modified Process (Alpha-1 MP) is used for augmentation therapy” PMID 30416054 ↗ Nov 2018 |
| Action | Restore | “Augmentation therapy with Prolastin® (Alpha₁-Proteinase Inhibitor [Human]) to increase the levels of alpha₁-PI has been used to treat individuals with AAT deficiency for over 20 years.” PMID 20920295 ↗ Sep 2010 |
| Modality | Protein / enzyme biologic | “Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1 MP)” NCT00295061 ↗ |
| Route | Intravenous | “administered weekly by IV infusion” NCT01983241 ↗ |